MOTS-c: What It Is, Where to Get It Prescribed, and What It Costs

MOTS-c is a 16-amino-acid peptide, and the unusual thing about it is where its gene sits. Almost every peptide in the body is encoded in the DNA of the cell nucleus. MOTS-c is encoded in the mitochondrial genome — the small, separate loop of DNA that mitochondria carry — inside a short open reading frame in the gene for the 12S ribosomal RNA. It was identified in a 2015 paper in Cell Metabolism from a group at the University of Southern California, and it belongs to a small family, alongside humanin, that changed the picture of mitochondria from energy factories taking orders from the nucleus to organelles that send their own signals back.

MOTS-c stands for "mitochondrial open reading frame of the 12S rRNA-c" — a location on the mitochondrial genome, not a function. Pharmacies supply it as the free base or as an acetate salt; both are the same peptide, and the FDA reviewed both forms together in July 2026.

MOTS-c is not a hormone in the classical sense and not a growth hormone secretagogue — it does not act on the pituitary the way ipamorelin or sermorelin do. It is not a GLP-1 medication and does not work through appetite. It is not a stimulant, despite the "cellular energy" language online. And it is not an approved drug for any indication anywhere. The most accurate description is a signalling peptide the body makes in small amounts, which researchers have given to animals in larger amounts to see what changes.

The central mechanism proposed in the original Cell Metabolism paper (2015) is metabolic rather than receptor-based. In cultured cells the peptide was reported to inhibit the folate cycle and the purine synthesis pathway tethered to it, causing a molecule called AICAR to accumulate. AICAR activates AMPK — the enzyme cells use as a low-fuel sensor, the same one exercise and calorie restriction switch on. So the described chain is: MOTS-c slows one pathway, a by-product builds up, and the cell reads it as a signal to burn rather than store. Skeletal muscle appeared to be the primary target.

A 2018 paper in Cell Metabolism from the same group reported that, when cells are stressed by glucose restriction, MOTS-c travels into the nucleus and changes which nuclear genes are switched on, in an AMPK-dependent way, interacting with stress-responsive transcription factors including NRF2. This is cell work, and the basis for calling MOTS-c a messenger from mitochondria to the nucleus.

A 2021 paper in Nature Communications reported that MOTS-c treatment was associated with better physical performance in young, middle-aged and old mice, with changes in skeletal muscle metabolism. The same paper reported that in humans, a bout of exercise raised the body's own MOTS-c in muscle and blood. That human finding is observational — what the body does after exercise, not what happens when the peptide is injected — but it is why MOTS-c is often called an "exercise-mimetic," a label for a proposed mechanism rather than a demonstrated effect in people.

A 2019 paper in the Journal of Molecular Medicine used ovariectomised mice, a standard model of post-menopausal metabolic change, and reported more brown-fat activity, less fat accumulation and less inflammatory infiltration in white fat in treated animals, again through AMPK.

A 2016 paper in Biochemical and Biophysical Research Communications, also in ovariectomised mice, reported less bone loss on micro-CT in treated animals and that MOTS-c inhibited RANKL-driven osteoclast formation in an AMPK-dependent way. This is why osteoporosis sat alongside obesity as a nominated use at the FDA's 2026 review. Mouse and cell data only.

This is the founding line of research. In the 2015 Cell Metabolism work, MOTS-c treatment in mice was reported to prevent both age-related insulin resistance and the insulin resistance and weight gain that develop on a high-fat diet. A 2021 paper in Aging added a genetic angle: an East Asian mitochondrial DNA variant that changes one amino acid in MOTS-c was associated, across three cohorts totalling 27,527 people, with a higher prevalence of type 2 diabetes in men — particularly sedentary men — and the variant peptide lost its insulin-sensitising activity in mice and cells.

The 2021 Nature Communications paper reported improved performance on physical tests in mice at every age tested, and that intermittent treatment started very late in life was associated with better physical capacity and a longer healthy lifespan. Those are mouse endpoints, as are the ovariectomy studies most often cited for MOTS-c in women: less fat gain, better glucose tolerance and less bone loss, all in mice.

This is the part worth reading twice. There are no randomised controlled trials of MOTS-c in humans. What exists in people falls into two categories that should not be blurred together.

The first is observational work measuring the body's own MOTS-c. Exercise raises it in muscle and blood (Nature Communications, 2021). A cross-sectional study of 225 people in Qatar (Frontiers in Endocrinology, 2019) reported lower serum MOTS-c in people with type 2 diabetes than in controls. A Chilean study of ten lean and ten obese adults (Journal of Investigative Medicine, 2018) and a 2025 study of 85 adults in Türkiye (Archives of Endocrinology and Metabolism) both found similar levels with and without obesity. None of these gave anyone MOTS-c.

The second is the closest thing to a human treatment trial, and it was not MOTS-c. CohBar, a company co-founded by the peptide's discoverers, developed a modified analogue called CB4211 and ran a Phase 1a study in 65 healthy adults (ascending doses over one week), then a Phase 1b study: randomised, double-blind and placebo-controlled, once-daily subcutaneous injections for four weeks in 20 adults with obesity and non-alcoholic fatty liver disease. The company reported in 2021 that the primary safety and tolerability endpoint was met with no serious adverse events, and described reductions in the liver enzymes ALT and AST, a fall in glucose, and a trend toward lower body weight on exploratory endpoints. Those were company announcements rather than a peer-reviewed publication, the analogue is a different molecule from the compounded peptide, and the program did not advance beyond Phase 1.

So the honest framing is: a coherent preclinical story, human observational data on the natural peptide, and one small early-phase study of a related analogue. Any page describing MOTS-c as clinically proven for weight, energy or longevity is overstating it.

• It does not establish that injected MOTS-c changes weight, glucose, fitness or lifespan in humans. Those trials have not been run.
• It does not establish an effect size or a timeline in people. Anything about "results in X weeks" is prescriber experience or extrapolation from mice.
• It does not establish that raising MOTS-c levels does what naturally high levels correlate with; two of the observational studies found levels rising with insulin resistance, not falling.
• It does not establish long-term safety over years of use, which is why prescribing is course-based and reviewed, and it does not establish efficacy for any condition as an approved treatment.

Most people report nothing they can point to. Some describe feeling slightly more energetic during training; others mild jitteriness on injection mornings that settles. Neither is a measure of anything, and noticing nothing in this window is normal.

If MOTS-c does what the animal work describes — shifting muscle toward using fuel rather than storing it — this is the window in which prescribers say they would expect to see it, and why a course is usually at least two vials. What is reported is subtle: better training tolerance, steadier afternoon energy, sometimes changes in fasting glucose or waist measurement. Nobody can put a number on it.

The mechanism is an exercise-signalling pathway, and the mice in the exercise study were tested on treadmills, not left in cages. Prescribers describe MOTS-c as something taken alongside a training and nutrition plan, not instead of one. A metabolic change from an injection alone is a job the evidence does not support.

There is no withdrawal and no rebound described in the literature; it is a peptide the body already makes. Whether anything persists depends on whether habits changed during the course. There is no tapering.

The directions are written in millilitres and insulin-syringe units because that is what you can read off the barrel. 0.25 mL is 25 units on a U-100 syringe; the 20mg/10mL strength is directed at 0.50 mL, which is 50 units. The number is printed on your medication.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated. The morning timing places the dose near the day's activity, and the mild alertness some people report is less welcome at night. The five-days-on, two-off pattern is a prescriber convention rather than a trial-derived schedule; the late-life mouse work used intermittent rather than daily dosing. Your directions will say.

20 doses at five per week is four weeks, which is why refills run on a 28-day cycle. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Keep it in the fridge between doses and out of light. Beyond-use dating runs from first puncture and is printed on the label.

Both get called "mitochondrial peptides," which hides how different they are. MOTS-c is a peptide the mitochondria themselves encode and release as a signal. SS-31 is a synthetic peptide that binds cardiolipin in the inner mitochondrial membrane, described as stabilising the membrane and the electron transport chain. SS-31 has been through human trials in mitochondrial disease; MOTS-c has not.

Semaglutide and tirzepatide reduce appetite and have large randomised human trials showing weight loss. MOTS-c works on fuel handling in muscle in animal models and has no human efficacy trial. They are not competing for the same job.

Both are prescribed around body composition, through different pathways. 5-Amino-1MQ is a small molecule described as inhibiting the enzyme NNMT in fat cells; MOTS-c is a peptide described as activating AMPK in muscle. The FUSION blend contains both. Neither has randomised human trials.

Identical medication. The pepti Pen is a pre-filled cartridge in a reusable click-dial injector, dosed in clicks rather than drawn from a vial with a syringe. It costs more and it removes the draw step. Neither is clinically better.